Argenica Therapeutics Limited (AGN) Fair Value & Analysis
Healthcare · AU · Market cap A$16.7M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0600 to A$0.0630 (+5.0%) since Jun 25, 2026. Share price −15.5% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0871 – A$0.7355 · fair‑value band A$0.0450 – A$0.0720 · the A$0.0900 price screens above the A$0.0630 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Argenica Therapeutics Limited (AGN) currently trades at A$0.0900, while our model-based Fair Value estimate is A$0.0630 — implying the stock looks roughly 30.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$1.0M. Revenue declined 77.9% year over year. The balance sheet holds a net cash position of A$10.6M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Argenica Therapeutics Limited reported revenue of A$3.2M in FY2024 versus A$200 in FY2020, a compound +1,025.9%/yr. Reported net income was −A$7.2M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Argenica Therapeutics Limited (AGN) undervalued?
What is the fair value of AGN?
What is the quality score of AGN?
What is the revenue of Argenica Therapeutics Limited (AGN)?
What is the net profit margin of AGN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.